Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • ASCI Milestone Awards
    • Video Abstracts
    • Conversations with Giants in Medicine
  • Reviews
    • View all reviews ...
    • Emerging therapeutic strategies in breast cancer (Oct 2026)
    • The cGAS-STING pathway: DNA sensing in health and disease (Jun 2026)
    • Neurodegeneration (Mar 2026)
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles
  • Search Articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • ASCI Milestone Awards
  • Video Abstracts
  • Conversations with Giants in Medicine
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Modeling human neurodegeneration with iPSCs: opportunities, limitations, and the challenge of aging
Shijie Wang, Lisa Elia, Weiyi Liu, Steven Finkbeiner
Shijie Wang, Lisa Elia, Weiyi Liu, Steven Finkbeiner
View: Text | PDF
Review

Modeling human neurodegeneration with iPSCs: opportunities, limitations, and the challenge of aging

  • Text
  • PDF
Abstract

Most neurodegenerative diseases reflect patient-specific combinations of polygenic risk variants interacting with aging and environmental factors, rather than a single causative mutation. Phase III clinical trial failure rates for neurodegenerative indications exceed 95%, reflecting in part the limitations of existing preclinical systems to fully model the human genetic context of disease. Patient-derived induced pluripotent stem cells (iPSCs) have the potential to address this shortcoming by faithfully recapitulating human cell biology and preserving each patient’s complete genetic architecture. This Review examines iPSC-based models of neurodegeneration across three themes. First, we discuss mechanisms revealed by these models, from convergent pathways uncovered by familial mutations to early evidence that sporadic disease biology is accessible at sufficient cohort scale. Second, we evaluate culture systems from 2-dimensional monocultures to organoids, examining how increasing complexity expands addressable biological questions while introducing trade-offs. Third, we address the aging problem: reprogramming erases epigenetic signatures of donor aging, removing the cellular context in which late-onset sporadic neurodegeneration emerges. We discuss strategies approximating aging in iPSC-derived neurons and highlight direct conversion strategies that preserve native epigenetic age, enabling access to age-dependent phenotypes. We propose a framework matching model systems to biological questions, improving mechanistic understanding and therapeutic development.

Authors

Shijie Wang, Lisa Elia, Weiyi Liu, Steven Finkbeiner

×

Figure 2

Disease-specific and convergent cellular phenotypes in iPSC-derived models of neurodegeneration.

Options: View larger image (or click on image) Download as PowerPoint
Disease-specific and convergent cellular phenotypes in iPSC-derived mode...
(A) 85%–95% of NDD cases are sporadic and 5%–15% carry a familial mutation. In contrast, approximately 95% of iPSC-based disease models to date have been built on high-penetrance familial mutations, representing a systematic gap in the field. (B) Patient-derived somatic cells (fibroblasts or PBMCs) can be reprogrammed to iPSCs and differentiated into disease-relevant cell types or converted directly into neurons by transdifferentiation, which preserves the donor’s epigenetic age. Five major iPSC-derived cell types are shown with their disease-associated phenotypes, including microglia, cortical neurons that include both excitatory neurons and inhibitory interneurons, dopaminergic neurons, motor neurons, and astrocytes. Color coding indicates the primary disease(s) in which each phenotype has been demonstrated with each cell type: AD (red), PD (green), LBD (orange), FTD (yellow), and ALS (blue). Lower: Key cellular phenotypes shared across multiple diseases are depicted, including synaptic dysfunction, axonal transport defects, glial dysfunction, endo-lysosomal and proteostasis dysfunction, mitochondrial dysfunction, and oxidative stress, underscoring the convergent biology of neurodegeneration across genetically distinct conditions. Aβ, amyloid-β; APP, amyloid precursor protein; PBMCs, peripheral blood mononuclear cells; pTau, phosphorylated tau.

Copyright © 2026 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts